ICIs in hepatocellular carcinoma: A comprehensive analysis of path forward for multimodal treatment strategies.
作者信息
Peng Shixuan, Chen Qisheng, Wu Yongjun
机构信息
Department of Oncology, Graduate Collaborative Training Base of The First People's Hospital of Xiangtan City, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Department of Pathology, Xiangtan Center Hospital, Xiangtan, China.
出版信息
Hepatol Commun. 2024 Aug 5;8(8). doi: 10.1097/HC9.0000000000000509. eCollection 2024 Aug 1.
Abstract
摘要
相似文献
1
ICIs in hepatocellular carcinoma: A comprehensive analysis of path forward for multimodal treatment strategies.肝细胞癌中的免疫检查点抑制剂：多模式治疗策略前进道路的综合分析
Hepatol Commun. 2024 Aug 5;8(8). doi: 10.1097/HC9.0000000000000509. eCollection 2024 Aug 1.
2
Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.经动脉化疗栓塞联合分子靶向药物加免疫检查点抑制剂治疗超出 up-to-seven 标准的不可切除肝细胞癌：倾向评分匹配分析。
Ann Med. 2024 Dec;56(1):2419993. doi: 10.1080/07853890.2024.2419993. Epub 2024 Nov 1.
3
Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma.经动脉化疗栓塞联合酪氨酸激酶抑制剂和/或免疫检查点抑制剂诱发的甲状腺功能减退与肝细胞癌患者总生存期的改善相关。
Cancer Immunol Immunother. 2025 May 24;74(7):217. doi: 10.1007/s00262-025-04073-5.
4
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges.肝细胞癌免疫治疗：反应预测因素、问题与挑战。
Int J Mol Sci. 2024 Oct 15;25(20):11091. doi: 10.3390/ijms252011091.
5
Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis.比较包括免疫检查点抑制剂在内的多种治疗方法后肝细胞癌患者的肿瘤反应和结局 - 系统评价和荟萃分析。
HPB (Oxford). 2024 May;26(5):618-629. doi: 10.1016/j.hpb.2024.02.003. Epub 2024 Feb 9.
6
Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC.经动脉治疗联合贝伐单抗加免疫检查点抑制剂作为局部晚期肝癌的新辅助治疗
Front Immunol. 2024 Dec 23;15:1469302. doi: 10.3389/fimmu.2024.1469302. eCollection 2024.
7
Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.放疗与免疫检查点抑制剂：联合治疗肝癌。
Int J Mol Sci. 2023 Nov 26;24(23):16773. doi: 10.3390/ijms242316773.
8
Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis.经动脉化疗栓塞联合酪氨酸激酶抑制剂和免疫检查点抑制剂与单纯酪氨酸激酶抑制剂和免疫检查点抑制剂治疗晚期肝细胞癌的疗效和安全性比较：一项系统评价和荟萃分析
World J Surg Oncol. 2025 Apr 7;23(1):126. doi: 10.1186/s12957-025-03788-0.
9
MAFLD-related hepatocellular carcinoma: Exploring the potent combination of immunotherapy and molecular targeted therapy.MAFLD 相关肝细胞癌：探索免疫治疗和分子靶向治疗的强强联合。
Int Immunopharmacol. 2024 Oct 25;140:112821. doi: 10.1016/j.intimp.2024.112821. Epub 2024 Jul 31.
10
Efficacy and safety of apatinib plus immune checkpoint inhibitors and transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma.阿帕替尼联合免疫检查点抑制剂和肝动脉化疗栓塞治疗晚期肝细胞癌的疗效和安全性。
J Cancer Res Clin Oncol. 2024 Jul 8;150(7):340. doi: 10.1007/s00432-024-05854-8.
本文引用的文献
1
Immunotherapy at all stages of hepatocellular carcinoma.肝细胞癌各阶段的免疫治疗。
Nat Med. 2024 Mar;30(3):640-641. doi: 10.1038/s41591-024-02828-8.
2
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
3
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.肝细胞癌患者与其他晚期实体瘤患者免疫治疗相关肝损伤的特征与结局
J Hepatol. 2024 Mar;80(3):431-442. doi: 10.1016/j.jhep.2023.10.040. Epub 2023 Nov 15.
4
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known.免疫检查点抑制剂的肝毒性：目前已知的情况。
Hepatol Commun. 2023 Feb 20;7(3):e0063. doi: 10.1097/HC9.0000000000000063. eCollection 2023 Mar 1.
5
Hepatocellular carcinoma.肝细胞癌
Lancet. 2022 Oct 15;400(10360):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6.
Zotero 插件